A nurse is collecting data from a client who is receiving sumatriptan. Which of the following is an expected outcome?

Sumatriptan is a selective serotonin receptor agonist (5-HT1B/1D agonist) classified as a triptan medication. Its primary indication is the acute treatment of migraine headaches and cluster headaches. It works by causing vasoconstriction of dilated cranial blood vessels and inhibiting the release of pro-inflammatory neuropeptides, thereby aborting the migraine attack and diminishing headache pain. The expected and desired therapeutic outcome is a significant reduction or elimination of the headache. Reduced cough is not associated with sumatriptan; cough suppression is a property of antitussives such as dextromethorphan. Muscle relaxation is not a mechanism of sumatriptan action; that effect is associated with skeletal muscle relaxants such as cyclobenzaprine. Decreased peripheral edema is associated with diuretics or medications that affect venous tone and is not a property of sumatriptan. A nurse collecting data to evaluate the effectiveness of sumatriptan should expect to find that the client's migraine headache has diminished or resolved, confirming the medication has achieved its therapeutic purpose.